A mobile application used to assess sports-related head and brain injuries is currently being tested for the detection and monitoring of neurological disorders.
BrainEye's mobile test is currently in clinical trials at Melbourne's Alfred Hospital. It digitizes a traditional eye movement test done in 60 seconds using a mobile device and uses AI to collect and measure over 20 ocular biomarkers.
Alfred is recruiting 500 participants for the trial, who treat a variety of neurological conditions including Alzheimer's disease, Parkinson's disease, epilepsy and multiple sclerosis.
Why is it important?
Data collected from the trial will help BrainEye develop commercial products that can be used to detect and track neurological diseases in the community.
“Early detection of any neurological condition is important, and the effectiveness of eye movement assessment in detecting abnormalities is well known, but testing is usually only performed in a clinical setting and only when it is too late. „This is often the case,“ explained clinician Joanne Fielding. Principal investigator and chief scientific officer at BrainEye.
The collected biomarkers are compared to measurements from mentally healthy individuals, enhancing BrainEye's recognition and understanding of normal and abnormal brain function.
bigger trends
To date, BrainEye has performed more than 25,000 eye movement tests, most of which were performed under major sports competition rules and focused on concussions and brain trauma.
CEO Richard Nash said: „For BrainEye, this is a huge leap forward, from testing its utility in sports to healthcare applications to help users identify neurodegenerative diseases such as Alzheimer's and Parkinson's. This is an exciting development as we move into the future.“ Alfred.
„This innovative technology has great potential to become a practical and efficient tool for early monitoring of disease progression in a variety of neurological conditions,“ said Dr. said Terence O'Brien, program director at Alfred Blaine.